Premier Alternatives

ImmunoGenesis

Houston, TX · Founded 2019 · Privately Held (backing)

Developer of immuno-oncology therapeutics designed to create cold tumor treatments. ImmunoGenesis is based in Houston, TX and was founded in 2019. It was valued at $142 million at its later-stage round in May 2025, the last priced event on record. It has raised $67.2 million across 1 recorded round; the latest was a $44.4 million early-stage round in Mar 2024.

PMV mark · valuation
$142.0M
Oct 2026
Priced at
its later-stage round
May 2025
Total raised
$67.2M
Last round
Early Stage VC
Mar 2024

ImmunoGenesis key facts

as of Oct 2026
  • Developer of immuno-oncology therapeutics designed to create cold tumor treatments.
  • ImmunoGenesis is valued at approximately $142.0M as of Oct 2026, set at its later-stage round, May 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $67.2M across 1 recorded rounds; the latest was Early Stage VC ($44.4M) in Mar 2024.
  • Notable investors include Service Provider Capital, ADIT Ventures, Magnetar Capital, PEAK6 Strategic Capital, 3Spoke Capital — 13 tracked in total.
  • ImmunoGenesis has filed 1 Form D with the SEC, most recently Apr 2024 ($44.4M sold to 88 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$142.0M

Valued at $142.0M at its later-stage round, May 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of ImmunoGenesis with a free account
  • ·The complete investor list: 13 names
  • ·Watch ImmunoGenesis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ImmunoGenesis funding rounds

1 rounds
Mar 2024Early Stage VC$44.4MSEC filing▮
Full funding history →

ImmunoGenesis valuation

ImmunoGenesis was valued at $142 million at its later-stage round in May 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has ImmunoGenesis raised?

ImmunoGenesis has raised $67.2 million in total; 1 of its rounds is on record. The largest on record was a $44.4 million early-stage round in Mar 2024.

ImmunoGenesis has filed 1 Form D with the SEC, most recently in Apr 2024 ($44.4 million sold to 88 investors).

ImmunoGenesis investors

13 investors are on record for ImmunoGenesis, including Service Provider Capital, ADIT Ventures, Magnetar Capital and PEAK6 Strategic Capital. By type, the record holds 4 venture capital firms, 2 family offices and 1 hedge fund. The early-stage round in Mar 2024 drew 88 investors.

About ImmunoGenesis

Developer of immuno-oncology therapeutics designed to create cold tumor treatments. The company specializes in immunotherapies to catalyze effective immune responses in immunologically cold cancers such as prostate, colorectal, and pancreatic cancer for the treatment of cancer patients, enabling healthcare professionals to get access to therapies that target key mechanisms of immune resistance.

Sector
Healthcare
HQ
Houston, TX, United States
Founded
2019
Employees
15
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.